利用常规血液检查与临床数据预测癌症免疫检查点抑制剂疗效
研究开发并评估了机器学习系统SCORPIO,利用常规血检(全血细胞计数和综合代谢谱)及临床特征,基于21种癌症类型、9,745例接受免疫检查点抑制剂(ICI)治疗的患者数据。在内部测试集中,SCORPIO预测总生存的中位时间依赖AUC(t)为0.763和0.759,优于肿瘤突变负荷(TMB)的0.503和0.543;预测临床获益的AUC为0.714和0.641,优于TMB的0.546和0.573。外部验证使用10项全球3期试验(4,447例,6种癌症)和西奈山卫生系统真实世界队列(1,159例,18种癌症),SCORPIO保持稳健性能并超越PD-L1免疫染色。
要点
- SCORPIO利用常规血检和临床数据预测ICI疗效,无需先进基因组或免疫学检测。
- 内部测试集中预测总生存中位AUC(t)为0.763和0.759,优于TMB的0.503和0.543。
- 外部验证中SCORPIO保持稳健性能,超越PD-L1免疫染色。
核心结论
- SCORPIO在内部和外部队列中均表现出稳健的预测性能,突显其跨癌种和医疗环境预测ICI治疗患者结局的潜力。
研究设计与样本
- 研究开发并评估了机器学习系统SCORPIO,使用常规血检(全血细胞计数和综合代谢谱)及临床特征。
- 数据来自21种癌症类型、9,745例接受ICI治疗的患者。
- SCORPIO在纪念斯隆凯特琳癌症中心17种癌症类型的1,628例患者数据上训练。
- 内部测试集包括19种癌症类型的2,511例患者。
- 外部验证使用10项全球3期试验(4,447例,6种癌症类型)和西奈山卫生系统真实世界队列(1,159例,18种癌症类型)。
主要发现
- 在内部测试集中,SCORPIO预测6、12、18、24和30个月总生存的中位时间依赖AUC(t)分别为0.763和0.759,优于TMB的中位AUC(t) 0.503和0.543。
- SCORPIO预测临床获益(肿瘤缓解或持续稳定)的AUC为0.714和0.641,优于TMB的AUC 0.546和0.573。
- 在外部队列中,SCORPIO预测ICI结局保持稳健性能,超越PD-L1免疫染色。
关键数值与推荐
- 内部测试集中预测总生存的中位AUC(t):SCORPIO为0.763和0.759,TMB为0.503和0.543。
- 内部测试集中预测临床获益的AUC:SCORPIO为0.714和0.641,TMB为0.546和0.573。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Predicting whether a patient with cancer will benefit from immune checkpoint inhibitors (ICIs) without resorting to advanced genomic or immunologic assays is an important clinical need. To address this, we developed and evaluated SCORPIO, a machine learning system that utilizes routine blood tests (complete blood count and comprehensive metabolic profile) alongside clinical characteristics from 9,745 ICI-treated patients across 21 cancer types. SCORPIO was trained on data from 1,628 patients across 17 cancer types from Memorial Sloan Kettering Cancer Center. In two internal test sets comprising 2,511 patients across 19 cancer types, SCORPIO achieved median time-dependent area under the receiver operating characteristic curve (AUC(t)) values of 0.763 and 0.759 for predicting overall survival at 6, 12, 18, 24 and 30 months, outperforming tumor mutational burden (TMB), which showed median AUC(t) values of 0.503 and 0.543. Additionally, SCORPIO demonstrated superior predictive performance for predicting clinical benefit (tumor response or prolonged stability), with AUC values of 0.714 and 0.641, compared to TMB (AUC = 0.546 and 0.573). External validation was performed using 10 global phase 3 trials (4,447 patients across 6 cancer types) and a real-world cohort from the Mount Sinai Health System (1,159 patients across 18 cancer types). In these external cohorts, SCORPIO maintained robust performance in predicting ICI outcomes, surpassing programmed death-ligand 1 immunostaining. These findings underscore SCORPIO's reliability and adaptability, highlighting its potential to predict patient outcomes with ICI therapy across diverse cancer types and healthcare settings.
引用
- Yoo SK, Fitzgerald CW, Cho BA, et al. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nat Med. 2025. PMID: 39762425. doi:10.1038/s41591-024-03398-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。